What’s going on with the AstraZeneca share price?

The AstraZeneca share price has been treading water for some time. Dr James Fox takes a closer look at possible catalysts, including a rising dividend.

| More on:
Concept of two young professional men looking at a screen in a technological data centre

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE:AZN) share price has fallen 8.4% over the past 12 months. It’s underperformed the wider FTSE 100. That’s certainly not something I thought I’d say a year ago. So, what’s going on with it?

Moving sideways

It’s been an underwhelming year for AstraZeneca stock, and there are no obvious reasons for this. The oncology-focused company is up 75.6% over five years, and it appears to have reached something of a plateau.

One setback was the perceived disappointing results of its datopotamab deruxtecan lung cancer trial in October. Jefferies analyst Stephen Barker suggested the trial results were “worse-than-expected,’ noting only a marginal improve in the condition of non-small cell lung cancer.

However, the US Food and Drug Administration has since been given the green light for the treatment for patients with treated advanced nonsquamous non-small cell lung cancer.

Datopotamab deruxtecan is just one of several factors that could have negatively impacted the share price. Of course, with AstraZeneca receiving a lot of attention during the pandemic, investors may have simply found better value elsewhere. The below chart tracks the company’s momentum over the past 12 months.

Source: TradingView

Possible catalysts

One possible catalyst for share price growth was announced on Thursday 11 April. Ahead of a key shareholder vote on pay for its long-standing chief executive Pascal Soriot, AstraZeneca promised to increase its dividend by 7% this year. The dividend yield currently sits at 2.12% — not particularly exciting.

The stock was up 1.1% in early trading.

There are also several catalysts in the form of drug approvals, including breast cancer treatment Truqap and nerve disorder treatment Wainua in the US. Imfinzi, which contributes an impressive 9% of the company’s revenues, was approved in China in November. Depending on the uptake in this huge market, it could be a substantial boost.

There’s also the matter of improved guidance. Management recently revised guidance upwards from the “high single-digit to low double-digit percentage.” If it can come through and start showing evidence of this, I’d expect further upward movement in the share price.

Of course, there are always ups and downs in drug and treatment development. Some treatments fail despite millions of pounds of investment.


AstraZeneca certainly doesn’t look like bad value. The pharma giant is currently trading at 16.8 times forward earnings, representing a 14.2% discount to the wider healthcare industry. And given modest growth expectations, this forward price-to-earnings (P/E) ratio falls to 14.5 times in 2025 and 12.5 times in 2026.

For me, one of the most important metrics is the price-to-earnings-to-growth (PEG) ratio. This is essentially the forward P/E ratio divided by the expected average annualised growth rate over the medium term. AstraZeneca’s PEG ratio is 1.4. Coupled with the small but handy dividend yield, this doesn’t scream value.

However, with global populations ageing and treatment costs becoming more realistic in the developing world, a lot of the value for pharma stocks is beyond the medium term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Group of young friends toasting each other with beers in a pub
Investing Articles

Taylor Wimpey just paid me £158.78. I’m aiming to turn that into a £100k yearly second income

Harvey Jones says small, regular dividend payments can turn a few pounds into a mighty second income, if he gives…

Read more »

A pastel colored growing graph with rising rocket.
Value Shares

These FTSE 250 shares are tipped to rise 14% to 18% in the next year!

Looking for the best FTSE 250 momentum shares to buy? Here are two that City analysts expect to soar in…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Lloyds’ share price is up 20% in 3 months! How high can it go?

Lloyds’ share price has ripped higher recently. Here, Edward Sheldon provides his view on the level it could potentially climb…

Read more »

Investing Articles

Why the Rolls-Royce share price could continue to outperform

The Rolls-Royce share price keeps moving forward, but this Fool thinks it's still behind where it ought to be after…

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

The City expects explosive growth in earnings from this almost-penny stock

It’s rare to find earnings predictions as robust as those for this not-quite-a-penny stock, so I’d research and consider it…

Read more »

Investing Articles

As earnings rise 600%, is Nvidia still the best AI stock to buy?

With the supply and demand equation still looking strong for Nvidia, is the stock still the best AI opportunity for…

Read more »

Value Shares

Cheap UK stocks are soaring! Here’s 1 to consider buying now

In recent weeks, many UK stocks have surged. Here, Edward Sheldon highlights a blue-chip FTSE 100 share he believes could…

Read more »

Investing Articles

Top alternatives to consider as the IAG share price climbs!

I've been bullish on IAG shares for some time, but as the IAG share price pushes upwards from its pandemic…

Read more »